anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A pressing issue in anesthesiology involves developing an understanding of the non-anesthetic effects of the medications typically used in intravenous and inhalation anesthesia methods. Few studies describe the effects of both intravenous and inhalational anesthetics on regional tissue perfusion is described under stable anesthetic conditions. There is the issue of whether inhalational anesthetics compromise regional tissue perfusion even though systemic parameters are within normal ranges. It is still debated how these effects may be different under pathophysiological conditions, such as cardiac surgery.

Maintaining tissue perfusion and oxygenation is the cornerstone of therapy for patients with cardiac disease. An imbalance in oxygen delivery and tissue oxygen consumption leads to anaerobic metabolism, cellular injury, and organ dysfunction, and is associated with poor outcomes. Consequently, monitoring tissue oxygen delivery and consumption status is of paramount importance in cardiac surgery patients. Routinely used monitors in intraoperative settings such as pulse oximetry, blood pressures, hemoglobin saturation levels, lactate, acid-base status, and central venous oxygen saturation levels all reflect tissue metabolism. Near-infrared spectroscopy (NIRS) is a non-invasive optical technique that can be used to continuously monitor tissue oxygen delivery and oxygen consumption status. Cerebral autoregulation can blunt the effect of impaired systemic oxygen delivery. Thus, cerebral NIRS may be a good predictor of neurological outcomes, but skeletal muscle NIRS serves as a follow-up indicator of many other postoperative complications due to impaired perfusion and oxygenation. Therefore, both cerebral and somatic monitoring may contribute to a more complete evaluation of hemodynamic competence. Obtaining the cerebral and somatic oxygenation levels are valuable to help in clinical management during cardiopulmonary bypass (CPB) and cardiac surgery as a whole.

The aim of this study was to evaluate the effect of total intravenous anesthesia (TIVA) and inhalational anesthesia techniques on tissue oxygenation in cardiac surgery. For this purpose, the effects of midazolam-based TIVA or sevoflurane-based inhalation anesthesia maintenance on intraoperative central and somatic tissue oxygenation parameters were compared in patients undergoing cardiac surgery.
Subjects will receive sipuleucel-T concurrently with enzalutamide (160 mg orally once daily). Enzalutamide treatment will start 2 weeks prior to the first leukapheresis and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
Targeting certain effector molecules to specific living cells, such as a cancer cells, or their constituents in an animal including a human. In the method of the invention sequential formation of specific binding pairs targets effector molecules in an amplified fashion to a particular target cell. Initially, a specific binding pair if formed between a target molecule on the target cell and a first reagent. This specific binding pair formation results from specific binding between the target molecule and a first functional group on the first reagent. Sequential specific binding pairs are then formed between the first reagent and a second reagent, the second reagent and a third reagent etc.. These sequential specific binding pairs form because each reagent has a second functional group that specifically binds to a first functional group present in the next reagent in the sequence. Amplification occurs because the first and second functional groups on each reagent are multivalent. Generally, the last reagent in the sequence has a first functional group, but has an effector group in place of the second functional group. The effector group may be either a diagnostic marker or a therapeutic molecule.
1,183,299. Foam bath compositions. HANS SCHWARZKOPF. 29 July, 1968 [28 July, 1967], No. 36162/68. Heading C5D. Foam bath compositions comprises a foaming agent and a grease restoring agent wherein the grease restoring agent is micro-encapsulated in a film-forming material which is capable of slowly dissolving in warm water, thereby to release the grease restoring agent into the bath water over a period of time. Grease restoring agents mentioned are mineral oil; peanut oil; olive oil; isopropyl myristate, palmitate or stearate; castor oil; almond oil; St. John's wort oil; oleic acid oleyl ester; cotton seed oil or sunflower seed oil. The film-forming materials mentioned are gelatin/gum arabic mixture, gelatin/sodium alginate mixture or succinated gelatin. Other conventional additives which may be present include glycols or polyglycols, urea or urea derivatives, inorganic salts such as phosphates, carbonates or bicarbonates; organic acids such as tartaric acid or citric acid, colouring substances, anti-microbial agents and perfumes.
Breast cancer is the most frequently diagnosed cancer in women, representing 26% of all female cancers. It is also the second leading cause of cancer related deaths in the US for women. Side effects of the cancer and treatment therapies may result in inactivity and inadequate intakes of various nutrients, including protein and vitamin D, associated with cardiovascular disease (CVD) and type 2 diabetes. High concentrations of systemic and local inflammation correlate well with CVD and diabetes risk. There is substantial evidence to support that incorporating physical activity and nutrition into one's lifestyle can reduce inflammation and, ultimately, the progression to CVD and diabetes. Understanding the role of exercise and diet management in the health of breast cancer survivors will allow us to translate these findings into therapy guidelines.
The rationale for this study is the need to proactively address health disparities associated with age-related skeletal muscle dysfunction. Age-related changes in muscle may be characterized by sarcopenia (i.e., loss of muscle mass) and/or myosteatosis (i.e., excessive intramuscular adipose tissue). These changes may result in physical impairments that may be exacerbated by the lack of a formal screening and diagnosis process for older adults in standard healthcare settings. Myosteatosis may compound the effects of sarcopenia and play a significant role the age-related functional decline and higher incidence of type 2 diabetes observed in African Americans in comparison to other ethnic/racial groups. The initial phase of the study will involve the assessment of older African Americans (n = 70) to characterize muscle size and quality in comparison to a younger reference group (n = 70). Participants randomly selected from the older subject pool will be assigned to either the Eccentric Exercise Group or the Concentric Exercise Group for 12 weeks of a supervised strengthening exercise regimen.
Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
A composition consists of an effective amount of a synthetic neutral fucosylated human milk oligosaccharide (“HMO”), an effective amount of a synthetic neutral non-fucosylated HMO, and one or more excipients acceptable for enteral administration to a non-infant human. In some embodiments, the synthetic neutral fucosylated HMO is 2′-fucosyllactose and the synthetic neutral non-fucosylated HMO is selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”). In certain embodiments, the mass ratio of 2′-FL to the selected LNnT or LNT is about 1.5 to about 4.5. In one embodiment, the synthetic neutral non-fucosylated HMO is lacto-N-neotetraose (“LNnT”). In certain embodiments, the one or more excipients acceptable for enteral administration to a human are selected from diluents, antioxidants, lubricants, colorants, binders, disintegrants, and combinations thereof. In various embodiments, the one or more excipients are effective to form a galenic unit dosage form selected from a capsule, a tablet, and a sachet.
PURPOSE: To obtain a cosmetic composition that is effective for inhibition of skin aging and suppression and prevention of dandruff by using sulfated saccharide, particularly sucrose sulfate or its salt or its complex, as an active ingredient, further adding excipient or diluent thereto. CONSTITUTION: This cosmetic composition contains 0.001-99 wt.%, particularly 1-10 wt.% of sucrose sulfate. The sucrose sulfate used here is, for example, sucrose polysulfate, particularly sucrose octasulfate. In addition, the sucrose polysulfate is preferably potassium or sodium sulfate of sucrose octasulfate. Further, an aluminum complex of sucrose octasulfate is preferred. This composition is effective for prevention and treatment of inflammation and infection and for treatment and prevention of non-bladder premalignant and carcinomatous diseases. Further, it is effective for burn, allergic diseases and immunological diseases.
The prodn. of 23-monoesters of 5-o-mycaminosyl tylonolide (OMT) and demycinosyltylosine (DMT) of formula (I) comprises reacting the parent antibiotic with an acylating agent in the presence of external base. Q is H for OMT or the gp. (II) for DMT. Pref. reaction is with an acyl chloride at -80 to 90≰C, or with an anhydride or reactive ester at -20≰C to room temp. The pref. bases are 2,4,6-collidine and pyridine. (I) are antibiotics or intermediates. The process provides selective acylation of only the 23-hydroxy gp.
Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
Participants will undergo the calibration phase beginning with moderate intensity training, followed by low, and high intensity training. Each training intensity will be performed 3 days a week for 2 weeks.
The present invention relates to the development of a hyaluronic acid and hyaluronic acid hybrid nanoparticle systems for the administration of active molecules, peptides, DNA and/or other hydrophilic or hydrophobic molecules, the composition of hyaluronic acid and hyaluronic acid hybrid nanoparticle systems, and the procedure for their development and use. These nanoparticles are made up of hyaluronic acid in salt form, preferentially the sodium salt of the polymers or hybridized with magnetic Fe particles. The nanoparticles are basically from natural polymers, biocompatibles and biodegradables. The nanoparticles allow the controlled release of the active molecules they transport and their orientation towards the target tissues. The present invention teaches a procedure to elaborate particles of hyaluronic acid with a diameter less than 180 nm., that incorporate an active ingredient, independent of its hydrophilic or hydrophobic nature. Procedures to produce the particles are described. The present invention will be useful in methods of transdermal drug delivery using hyaluronic acid nanoparticles, among other uses.
<P>PROBLEM TO BE SOLVED: To provide an iron preparation for effectively replenishing iron into living body without any side effects.  <P>SOLUTION: The subject composition for replenishing iron components intended for humans or animals comprises a nontoxic salt or an intramolecular ester of a hexose-derived acid and an iron compound. Food, or the like, containing the composition is provided. A method for preventing or treating sideropenia involving administering humans or animals with the composition or the food is provided. A method for mitigating side effects caused by the iron compound is also provided.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
1,135,987. Rubella vaccine; attenuating viruses. RECHERCHE ET INDUSTRIE THERAPEUTIQUES. 21 Oct., 1966, No. 47399/66. Heading A5B. Virulent Rubella virus is attenuated for use in a vaccine against Rubella, by subjecting it to at least fifteen serial passages on primary rabbit kidney tissue cultures. Preferably between 20 and 60 such passages are employed at a temperature of up to 36‹C, each passage being of from 3 to 6 days' duration. The virus may be obtained from throat swabs, urine or gargle samples from a clinical case of Rubella, and may be stored frozen, or inoculated into a suitable tissue culture, e.g. primary African green monkey kidney monolayers for isolation prior to attenuation. The rabbit kidney cell cultures are preferably from rabbits not more than 3 weeks old. After the final passage, the cells are separated from the supernatant fluid by filtration or centrifugation, leaving the virus in the medium. After titration of the virus strength and safety testing, the virus preparation is either freeze dried or stored frozen at -60‹C, and may be used as a vaccine by subcutaneous or intramuscular administration.
By 2050 the number of adults living with obesity in the UK will rise with approximately one in four in the adult population. This rising trend is not equitable, with higher prevalence in socially disadvantaged groups. There is an apparent paradox of not being able to provide food for the family to eat, a feature of food insecurity and living with obesity. With the current cost-of-living crisis, there is a challenge to afford both food and fuel bills. Environmentally sustainable and healthy diets are proposed to improve public health and reduce the impact of the food system on the environment, while also improving diet quality. However, healthier foods tend to be nearly three times more expensive than unhealthy foods, and this provides a challenge for citizens on low incomes. In this review, we explore some of the evidence for solutions in the retail food environment to support the UK food system to be safe, nutritious, environmentally friendly and fair for all. We highlight the value of co-production in research, to give value and power to the lived experience to address these inequalities. Our multidisciplinary research approach within the FIO Food research grant will generate new insights into modifiable and potentially impactful changes to the UK food system, specifically for the retail food sector. We believe that the co-creation, design and delivery of research with those living with obesity and food insecurity will help to transform the UK food system for health and the environment in this vulnerable group.
Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Participants will receive methotrexate weekly for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
Barrett's esophagus (BE) is a metaplasia of normal squamous epithelium. BE can progressively develop more abnormal features like low-grade intraepithelial dysplasia (LGID), high-grade intraepithelial dysplasia (HGID) before ultimately developing esophageal adenocarcinoma (EAC), with a low 5-year survival rate of 20 % or less. Recent evidence for the existence of cancer stem cells (CSCs) has advanced our understanding of cancer and has opened doors to new therapeutic strategies in cancer treatment. The fundamental goals of this project are to determine the effectiveness of endoscopic mucosal resection (EMR) and radiofrequency ablation (RFA) on eradication of putative intestinal stem cell markers that are overexpressed in BE with HGID and EAC. A better understanding of the cellular mechanisms that regulate the progression from normal squamous mucosa to EAC has enormous implications in the diagnosis and treatment of esophageal cancer. The presence of a CSC in esophageal cancer has been reported in both dysplastic BE/ EAC as well as in mouse models of the disease. The central hypotheses of the current proposal are: elimination of cells expressing stem cell markers occurs after ablative therapies (EMR/RFA) to eradicate BE with HGID/ EAC, and monitoring of stem cell marker expression during follow-up will correlate with disease recurrence or appropriate clinical response. Recently, we have reported that DCLK1, although minimally expressed in normal distal esophageal squamous mucosa, is markedly expressed in BE epithelium and EAC. We will test our central hypotheses with the following specific aims: 1. To prospectively characterize the cell specific expression patterns of putative intestinal stem cell biomarkers in BE patients and correlate them with serum/plasma protein expression and disease progression, 2. to examine prospectively the effects of EMR/RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence, and 3. to examine prospectively the effects on EMR/ RFA on esophageal-related quality of life and dysphagia during the endoscopic intervention period as well as following completion. The studies proposed have the potential to offer new insights for both the early diagnosis and monitoring of therapeutic response of future therapies for EAC. Moreover, these studies may identify novel biomarkers that can aid in the confirmation of HGID and potentially predict disease onset, progression and/or recurrence. Finally, these studies have the potential to provide preliminary data that will serve as the rationale for large scale multicenter trials to compare the effectiveness of EMR and RFA in BE with respect to clinical outcome, molecular features and effect on putative tumor stem cells. The recent identification of DCLK1 as a marker that distinguishes between normal and tumor stem cells in a rodent model of intestinal tumorigenesis lends support for our rationale for examining DCLK1 as a potential mediator of the neoplastic response in BE.
Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature]. Protect from light. Do not permit to freeze.

Marcaine® 0.5% with epinephrine 1:200,000 injection (as bitartrate) – Sterile isotonic solutions containing sodium chloride. Each 1 mL contains 5 mg bupivacaine hydrochloride and 0.0091 mg epinephrine bitartrate, with 0.5 mg sodium metabisulfite, 7 mg sodium chloride, 0.001 mL monothioglycerol, and 2 mg ascorbic acid as antioxidants, 0.0017 mL 60% sodium lactate buffer, and 0.1 mg edetate calcium disodium as stabilizer. The pH of these solutions is adjusted with sodium hydroxide or hydrochloric acid. Solutions of bupivacaine that contain epinephrine should not be autoclaved and should be protected from light. Do not use the solution if its colour is pinkish or darker than slightly yellow or if it contains a precipitate.

Marcaine® 0.5% with epinephrine 1:200,000 injection (NDC 31382-557-05) is available in cardboard boxes containing 5 blisters of 10 × 1.8 mL dental cartridges.

Manufactured for CARESTREAM DENTAL a division of Caresteam Health, Inc

by NOVOCOL Pharmaceutical of Canada Inc, Cambridge, Ontario, Canada N1R6X3
PURPOSE: To explore how boxed warning (BW) information fits within the context of prescribers' overall treatment decision-making and communication with patients.
METHODS: In-depth interviews (N = 52) were conducted with primary care providers and specialists. Participants were presented with one of two prescribing scenarios: (1) estrogen vaginal inserts to treat vulvovaginal atrophy (VVA) associated with menopause; or (2) direct-acting antivirals (DAA) to treat chronic hepatitis C virus infection (HCV). The semi-structured interviews explored participants' treatment decision-making within the scenario, reactions to current prescribing information for a product within the FDA-approved drug class, as well as their perceptions of BWs generally.
RESULTS: Across scenarios, providers described that the BW is only one of several factors that influence treatment decision-making. In the VVA scenario, symptom severity, family history, and experience with nonprescription drugs were raised as common factors that influence prescribing considerations; compared to comorbid infections, viral load, and HCV genotype in the HCV scenario. Perceptions of the DAA BW were generally positive or neutral, as many participants found the information important and appropriate. The VVA BW was viewed less favorably, with many participants stating the BW overstates the risk for this drug.
CONCLUSIONS: Findings suggest that BWs are one of several factors that influence providers' treatment decisions, and BW influence largely depends on context. Providers across scenarios expressed notable differences in their perceptions of the risk information provided in the presented BWs; however, across scenarios participants expressed consideration of how patients may perceive the BW.
After an initial baseline data collection visit to the dental clinic, patients will be placed in the virtual reality (VR) group or the no VR group. Caregivers in the VR group will be given VR glasses. They will be instructed how to access the video and use the glasses. The child/wearer of the glasses will feel immersed in the three-dimensional environment and be able to look around the room as they move down the hallways in the video. The caregiver will be encouraged to have the child wear the VR glasses as often as possible and record the number of times the video is watched. The caregiver will fill out a "records form" which will include the date and time the video was watched. Both groups will then return to the clinic for follow up data collection visit.
PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), slow responders that are then randomized to full PE will have sessions once a week for eight weeks. During these 60 minute sessions, participants will practice in vivo and imaginal exposure and continue these exposure exercises every day at home.
MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, we work to provide access within health insurance constraints.
In binocular vision, the relative strength of the input from the two eyes can have significant functional impact. These inputs are typically balanced; however, in some conditions (e.g., amblyopia), one eye will dominate over the other. To quantify imbalances in binocular vision, we have developed the Dichoptic Contrast Ordering Test (DiCOT). Implemented on a tablet device, the program uses rankings of perceived contrast (of dichoptically presented stimuli) to find a scaling factor that balances the two eyes. We measured how physical interventions (applied to one eye) affect the DiCOT measurements, including neutral density (ND) filters, Bangerter filters, and optical blur introduced by a +3-diopter (D) lens. The DiCOT results were compared to those from the Dichoptic Letter Test (DLT). Both the DiCOT and the DLT showed excellent test-retest reliability; however, the magnitude of the imbalances introduced by the interventions was greater in the DLT. To find consistency between the methods, rescaling the DiCOT results from individual conditions gave good results. However, the adjustments required for the +3-D lens condition were quite different from those for the ND and Bangerter filters. Our results indicate that the DiCOT and DLT measures partially separate aspects of binocular imbalance. This supports the simultaneous use of both measures in future studies.